These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 27228981)
41. Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare. Wang C; Kane R; Levenson M; Kelman J; Wernecke M; Lee JY; Kozlowski S; Dekmezian C; Zhang Z; Thompson A; Smith K; Wu YT; Wei Y; Chillarige Y; Ryan Q; Worrall C; MaCurdy TE; Graham DJ JAMA Intern Med; 2016 Dec; 176(12):1818-1825. PubMed ID: 27775769 [TBL] [Abstract][Full Text] [Related]
43. Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Rodby RA; Umanath K; Niecestro R; Bond TC; Sika M; Lewis J; Dwyer JP; Drugs R D; 2015 Sep; 15(3):271-9. PubMed ID: 26239948 [TBL] [Abstract][Full Text] [Related]
44. The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Fuller DS; Pisoni RL; Bieber BA; Port FK; Robinson BM Am J Kidney Dis; 2013 Dec; 62(6):1213-6. PubMed ID: 24140369 [No Abstract] [Full Text] [Related]
45. A strategy to reduce inflammation and anemia treatment's related costs in dialysis patients. Di Iorio BR; Di Micco L; Russo L; Nardone L; De Simone E; Sirico ML; Di Natale G; Russo D G Ital Nefrol; 2018 Feb; 35(1):. PubMed ID: 29390245 [TBL] [Abstract][Full Text] [Related]
46. Is case-mix adjustment necessary for an expanded dialysis bundle? Hirth RA; Wolfe RA; Wheeler JR; Roys EC; Tedeschi PJ; Pozniak AS; Wright GT Health Care Financ Rev; 2003; 24(4):77-88. PubMed ID: 14628401 [TBL] [Abstract][Full Text] [Related]
47. When payment systems collide: the effect of hospitalization on anemia in renal dialysis patients. Turenne MN; Hirth RA; Messana JM; Turner JS; Sleeman KK; Wheeler JR Med Care; 2010 Apr; 48(4):296-305. PubMed ID: 20195175 [TBL] [Abstract][Full Text] [Related]
48. Prospective analysis of global costs for maintenance of patients with ESRD. Ploth DW; Shepp PH; Counts C; Hutchison F Am J Kidney Dis; 2003 Jul; 42(1):12-21. PubMed ID: 12830452 [TBL] [Abstract][Full Text] [Related]
49. Rebasing the Medicare payment for dialysis: rationale, challenges, and opportunities. Wish D; Johnson D; Wish J Clin J Am Soc Nephrol; 2014 Dec; 9(12):2195-202. PubMed ID: 25189926 [TBL] [Abstract][Full Text] [Related]
50. The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: a systematic review. Ferguson T; Xu Y; Gunasekara R; Lerner B; Macdonald K; Rigatto C; Tangri N; Komenda P Am J Nephrol; 2015; 41(2):89-97. PubMed ID: 25721696 [TBL] [Abstract][Full Text] [Related]
51. Total Red Blood Cell Transfusions for Chronic Hemodialysis Patients in a Single Center, 2009-2013. Albright RC; Dillon JJ; Hocum CL; Stubbs JR; Johnson PM; Hickson LJ; Williams AW; Dingli D; McCarthy JT Nephron; 2016; 133(1):23-34. PubMed ID: 27081860 [TBL] [Abstract][Full Text] [Related]
52. Medicare programs: changes to the end-stage renal disease prospective payment system transition budget-neutrality adjustment. Interim final rule with comment period. Centers for Medicare & Medicaid Services (CMS), HHS Fed Regist; 2011 Apr; 76(66):18930-4. PubMed ID: 21491804 [TBL] [Abstract][Full Text] [Related]
53. Hospital treatment for fluid overload in the Medicare hemodialysis population. Arneson TJ; Liu J; Qiu Y; Gilbertson DT; Foley RN; Collins AJ Clin J Am Soc Nephrol; 2010 Jun; 5(6):1054-63. PubMed ID: 20430944 [TBL] [Abstract][Full Text] [Related]
54. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea. Kang RY; Lee J; Lee YH; Lee HS; Jeong JH; Lee YJ Int J Clin Pharm; 2012 Aug; 34(4):651-7. PubMed ID: 22729393 [TBL] [Abstract][Full Text] [Related]
55. Potential effects of the new Medicare Prospective Payment System on drug prescription in end-stage renal disease care. Winkelmayer WC Blood Purif; 2011; 31(1-3):66-9. PubMed ID: 21228569 [TBL] [Abstract][Full Text] [Related]
56. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. Powe NR; Griffiths RI; Watson AJ; Anderson GF; de Lissovoy G; Greer JW; Herbert RJ; Milam RA; Whelton PK J Am Soc Nephrol; 1994 Jan; 4(7):1455-65. PubMed ID: 8161727 [TBL] [Abstract][Full Text] [Related]
57. Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later. Weiner DE; Winkelmayer WC Am J Kidney Dis; 2013 Dec; 62(6):1217-20. PubMed ID: 24267389 [No Abstract] [Full Text] [Related]
58. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients. Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901 [TBL] [Abstract][Full Text] [Related]
59. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015). Park H; Liu X; Henry L; Harman J; Ross EA BMC Nephrol; 2018 Nov; 19(1):318. PubMed ID: 30413150 [TBL] [Abstract][Full Text] [Related]
60. The initial impact of Medicare's new prospective payment system for kidney dialysis. Hirth RA; Turenne MN; Wheeler JR; Nahra TA; Sleeman KK; Zhang W; Messana JA Am J Kidney Dis; 2013 Oct; 62(4):662-9. PubMed ID: 23769138 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]